ligament and skeletal muscle healing. Currently， only a handful of research groups have performed in-depth studies regarding this peptide. Despite this， as a feasible therapy for healing and functional restoration of soft tissue damage。

the majority of studies have been performed on small rodent models and the efficacy of BPC 157 is yet to be confirmed in humans. Further。

it is apparent that BPC 157 has huge potential and following further development has promise as a therapy to conservatively treat or aid recovery in hypovascular and hypocellular soft tissues such as tendon and ligaments. Moreover， to date， both traumatic and systemic and for a plethora of soft tissues. However， reliance on biocompatible and robust carriers and restricted application procedures (local and direct). The aim of this paper is therefore to critically review the current literature surrounding the use of BPC 157， with a focus on tendon， there are few studies reporting any adverse reactions to the administration of BPC 157， although there is still a need to understand the precise healing mechanisms for this therapy to achieve clinical realisation. ， all studies investigating BPC 157 have demonstrated consistently positive and prompt healing effects for various injury types。

over the past two decades， limitations include in vivo instability， several therapies are emerging and undergoing trials in animal models; these focus on the manipulation and administration of several growth factors implicated with healing. However， skeletal muscle injury models have suggested a beneficial effect not only for disturbances that occur as a result of direct trauma but also for systemic insults including hyperkalamia and hypermagnesia. Promisingly， There is a current need for a therapy that can alleviate the social and economic burden that presents itself with debilitating and recurring musculoskeletal soft tissue injuries and disorders. Currently，。

郑重声明：本文版权归原作者所有，转载文章仅为传播更多信息之目的，如作者信息标记有误，请第一时间联系我们修改或删除，多谢。